查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1344292

藥品給藥市場：按給藥途徑、按應用劃分：2023-2032 年全球機會分析與產業預測

Pharmaceutical Drug Delivery Market By Route of Administration, By Application : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 236 Pages | 商品交期: 2-3個工作天內

價格

藥品輸送市場預計到 2022 年將達到 14,987.2 億美元，到 2032 年將達到 23,072.7 億美元，2023 年至 2032 年的複合年增長率為 4.4%。Masu。

醫藥給藥市場-IMG1

心血管疾病、糖尿病、癌症、呼吸系統疾病等慢性疾病的特徵是需要長期藥物治療。 這些疾病需要定期用藥來控制症狀、減緩疾病進展並維持生活品質。 因此，對有效藥物輸送系統的需求不斷增加，從而推動了市場的成長。 國際糖尿病聯盟（IDF）估計，到2021年，大約四分之三的糖尿病成年人將生活在低收入和中等收入國家，西太平洋地區將有大約2.06億人被診斷出患有糖尿病。

例如，2022 年 5 月，美國食品藥物管理局 (FDA) 批准了 Mounjaro，一種治療 2 型糖尿病的新型注射給藥產品。 因此，糖尿病盛行率的增加導致了對治療糖尿病非常有效的先進胰島素輸送系統的開發。 此外，心血管疾病、關節炎、神經退化性疾病和骨質疏鬆症等與年齡相關的疾病的盛行率不斷增加，對有效的藥物傳遞產生了巨大的需求。

例如，2023 年 1 月，全球製藥業領先者百健 (Biogen) 的阿茲海默症治療藥物 LEQEMBI 獲得美國食品藥物管理局 (FDA) 批准。 LEQEMBI是一種單株抗體定向靜脈給藥藥物，可有效治療阿茲海默症。 因此，新的標靶藥物遞送和控釋製劑的開發將進一步促進市場成長。 然而，嚴格的監管要求增加了新藥物輸送技術的時間、成本和複雜性，並可能抑制市場成長。 此外，與新藥物輸送研發相關的高成本對市場成長有負面影響。

同時，對先進藥物輸送系統的需求不斷增長預計將為預測期內的市場成長創造利潤豐厚的機會。 這是由於慢性病盛行率不斷上升、治療結果改善以及有利於先進藥物輸送系統開發的報銷政策的存在。

目錄

第1章簡介

第 2 章執行摘要

第3章市場概述

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭強度
  • 市場動態
    • 促進因素
      • 各種慢性疾病的增加
      • 藥物傳□□輸系統的技術進步
    • 抑制因素
      • 嚴格的給藥審批監理要求
    • 機會
      • 對先進輸送系統的需求不斷增加
  • 新冠肺炎 (COVID-19) 市場影響分析

第 4 章藥物給藥市場：依給藥途徑劃分

  • 摘要
  • 口服給藥
  • 鼻腔給藥
  • 眼部藥物輸送
  • 局部給藥
  • 其他藥物輸送

第5章藥物給藥市場：依應用

  • 摘要
  • 癌症
  • 糖尿病
  • 心血管疾病
  • 其他

第6章藥物給藥市場：依地區

  • 摘要
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 韓國
    • 其他亞太地區
  • 拉丁美洲/中東/非洲
    • 巴西
    • 沙烏地阿拉伯
    • 南非
    • 其他領域

第7章競爭態勢

  • 簡介
  • 關鍵成功策略
  • 10家主要公司的產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 2022 年主要公司的定位

第8章公司簡介

  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Bayer AG
  • Cipla Ltd
  • Amgen Inc.
Product Code: A06102

According to a new report published by Allied Market Research, titled, "Pharmaceutical Drug Delivery Market," The pharmaceutical drug delivery market was valued at $1,498.72 billion in 2022, and is estimated to reach $2307.27 billion by 2032, growing at a CAGR of 4.4% from 2023 to 2032.

Pharmaceutical Drug Delivery Market - IMG1

Chronic diseases, such as cardiovascular disorders, diabetes, cancer, and respiratory diseases, are characterized by long-term medication treatment. These conditions require regular administration of drugs to control symptoms, slow disease progression, or maintain quality of life. This has increased the demand for effective drug delivery systems, thereby driving the market growth. According to International Diabetes Federation (IDF), in 2021, it was estimated that about 3 in 4 adults with diabetes live in low and middle-income countries and approximately 206 million people were diagnosed with diabetes in western pacific.

For instance, in May 2022, U.S. Food and Drug Administration (FDA), approved new injectable delivery product, Mounjaro to treat type 2 diabetes. Thus, the rise in prevalence of diabetes has led to the development of advanced insulin delivery systems, which are highly effective to treat diabetes. In addition, growth in prevalence of age-related diseases such as cardiovascular disorders, arthritis, neurodegenerative diseases, and osteoporosis have created a significant demand for effective drug delivery.

For instance, in January 2023, Biogen Inc., one of the global leader in pharmaceutical industry, received U.S. Food and Drug Administration (FDA) approval for LEQEMBI to treat Alzheimer's disease. LEQEMBI is a monoclonal antibody directed intravenous drug delivery medication that effectively treats Alzheimer's disease. Thus, development of new targeted drug delivery and controlled release formulation further contribute toward the market growth. However, stringent regulatory requirements can increase the time, cost, and complexity of new drug delivery technologies and restrain market growth. Furthermore, high costs associated with research and development of new drug delivery negatively impact market growth.

On the other hand, an increase in demand for advanced drug delivery systems is expected to create lucrative opportunities for market growth during the forecast period. This is attributed to the increase in prevalence of chronic diseases, enhanced treatment outcomes, and availability of favorable reimbursement policies for the development of advanced drug delivery systems.

The pharmaceutical drug delivery market is segmented on the basis of route of administration, application, and region. On the basis of route of administration, the market is classified into oral drug delivery, nasal drug delivery, ocular drug delivery, topical drug delivery, and other drug delivery. As per application, the market is categorized into cancer, diabetes, cardiovascular diseases, and others.

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global pharmaceutical drug delivery market are: Bayer AG, Cipla Ltd, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Amgen Inc., Pfizer Inc., Sanofi. Key players operating in the market have adopted product launch and product approval as their key strategies to expand their market share and product portfolio.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pharmaceutical drug delivery market analysis from 2022 to 2032 to identify the prevailing pharmaceutical drug delivery market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the pharmaceutical drug delivery market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global pharmaceutical drug delivery market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Route of Administration

  • Topical drug delivery
  • Other drug delivery
  • Oral drug delivery
  • Nasal drug delivery
  • Ocular drug delivery

By Application

  • Cancer
  • Diabetes
  • Cardiovascular Diseases
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Amgen Inc.
    • Bayer AG
    • Cipla Ltd
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi S.A.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in prevalence of various chronic diseases
      • 3.4.1.2. Technological advancement in drug delivery systems
    • 3.4.2. Restraints
      • 3.4.2.1. Stringent regulatory requirements for the approval of pharmaceutical drug delivery
    • 3.4.3. Opportunities
      • 3.4.3.1. Increase in demand for advanced delivery systems
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Oral drug delivery
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Nasal drug delivery
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Ocular drug delivery
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Topical drug delivery
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country
  • 4.6. Other drug delivery
    • 4.6.1. Key market trends, growth factors and opportunities
    • 4.6.2. Market size and forecast, by region
    • 4.6.3. Market share analysis by country

CHAPTER 5: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Cancer
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Diabetes
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Cardiovascular Diseases
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Others
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country

CHAPTER 6: PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast By Region
  • 6.2. North America
    • 6.2.1. Key trends and opportunities
    • 6.2.2. Market size and forecast, by Route of Administration
    • 6.2.3. Market size and forecast, by Application
    • 6.2.4. Market size and forecast, by country
      • 6.2.4.1. U.S.
      • 6.2.4.1.1. Key market trends, growth factors and opportunities
      • 6.2.4.1.2. Market size and forecast, by Route of Administration
      • 6.2.4.1.3. Market size and forecast, by Application
      • 6.2.4.2. Canada
      • 6.2.4.2.1. Key market trends, growth factors and opportunities
      • 6.2.4.2.2. Market size and forecast, by Route of Administration
      • 6.2.4.2.3. Market size and forecast, by Application
      • 6.2.4.3. Mexico
      • 6.2.4.3.1. Key market trends, growth factors and opportunities
      • 6.2.4.3.2. Market size and forecast, by Route of Administration
      • 6.2.4.3.3. Market size and forecast, by Application
  • 6.3. Europe
    • 6.3.1. Key trends and opportunities
    • 6.3.2. Market size and forecast, by Route of Administration
    • 6.3.3. Market size and forecast, by Application
    • 6.3.4. Market size and forecast, by country
      • 6.3.4.1. Germany
      • 6.3.4.1.1. Key market trends, growth factors and opportunities
      • 6.3.4.1.2. Market size and forecast, by Route of Administration
      • 6.3.4.1.3. Market size and forecast, by Application
      • 6.3.4.2. France
      • 6.3.4.2.1. Key market trends, growth factors and opportunities
      • 6.3.4.2.2. Market size and forecast, by Route of Administration
      • 6.3.4.2.3. Market size and forecast, by Application
      • 6.3.4.3. UK
      • 6.3.4.3.1. Key market trends, growth factors and opportunities
      • 6.3.4.3.2. Market size and forecast, by Route of Administration
      • 6.3.4.3.3. Market size and forecast, by Application
      • 6.3.4.4. Italy
      • 6.3.4.4.1. Key market trends, growth factors and opportunities
      • 6.3.4.4.2. Market size and forecast, by Route of Administration
      • 6.3.4.4.3. Market size and forecast, by Application
      • 6.3.4.5. Spain
      • 6.3.4.5.1. Key market trends, growth factors and opportunities
      • 6.3.4.5.2. Market size and forecast, by Route of Administration
      • 6.3.4.5.3. Market size and forecast, by Application
      • 6.3.4.6. Rest of Europe
      • 6.3.4.6.1. Key market trends, growth factors and opportunities
      • 6.3.4.6.2. Market size and forecast, by Route of Administration
      • 6.3.4.6.3. Market size and forecast, by Application
  • 6.4. Asia-Pacific
    • 6.4.1. Key trends and opportunities
    • 6.4.2. Market size and forecast, by Route of Administration
    • 6.4.3. Market size and forecast, by Application
    • 6.4.4. Market size and forecast, by country
      • 6.4.4.1. Japan
      • 6.4.4.1.1. Key market trends, growth factors and opportunities
      • 6.4.4.1.2. Market size and forecast, by Route of Administration
      • 6.4.4.1.3. Market size and forecast, by Application
      • 6.4.4.2. China
      • 6.4.4.2.1. Key market trends, growth factors and opportunities
      • 6.4.4.2.2. Market size and forecast, by Route of Administration
      • 6.4.4.2.3. Market size and forecast, by Application
      • 6.4.4.3. India
      • 6.4.4.3.1. Key market trends, growth factors and opportunities
      • 6.4.4.3.2. Market size and forecast, by Route of Administration
      • 6.4.4.3.3. Market size and forecast, by Application
      • 6.4.4.4. Australia
      • 6.4.4.4.1. Key market trends, growth factors and opportunities
      • 6.4.4.4.2. Market size and forecast, by Route of Administration
      • 6.4.4.4.3. Market size and forecast, by Application
      • 6.4.4.5. South Korea
      • 6.4.4.5.1. Key market trends, growth factors and opportunities
      • 6.4.4.5.2. Market size and forecast, by Route of Administration
      • 6.4.4.5.3. Market size and forecast, by Application
      • 6.4.4.6. Rest of Asia-Pacific
      • 6.4.4.6.1. Key market trends, growth factors and opportunities
      • 6.4.4.6.2. Market size and forecast, by Route of Administration
      • 6.4.4.6.3. Market size and forecast, by Application
  • 6.5. LAMEA
    • 6.5.1. Key trends and opportunities
    • 6.5.2. Market size and forecast, by Route of Administration
    • 6.5.3. Market size and forecast, by Application
    • 6.5.4. Market size and forecast, by country
      • 6.5.4.1. Brazil
      • 6.5.4.1.1. Key market trends, growth factors and opportunities
      • 6.5.4.1.2. Market size and forecast, by Route of Administration
      • 6.5.4.1.3. Market size and forecast, by Application
      • 6.5.4.2. Saudi Arabia
      • 6.5.4.2.1. Key market trends, growth factors and opportunities
      • 6.5.4.2.2. Market size and forecast, by Route of Administration
      • 6.5.4.2.3. Market size and forecast, by Application
      • 6.5.4.3. South Africa
      • 6.5.4.3.1. Key market trends, growth factors and opportunities
      • 6.5.4.3.2. Market size and forecast, by Route of Administration
      • 6.5.4.3.3. Market size and forecast, by Application
      • 6.5.4.4. Rest of LAMEA
      • 6.5.4.4.1. Key market trends, growth factors and opportunities
      • 6.5.4.4.2. Market size and forecast, by Route of Administration
      • 6.5.4.4.3. Market size and forecast, by Application

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

  • 8.1. F. Hoffmann-La Roche Ltd.
    • 8.1.1. Company overview
    • 8.1.2. Key Executives
    • 8.1.3. Company snapshot
    • 8.1.4. Operating business segments
    • 8.1.5. Product portfolio
    • 8.1.6. Business performance
  • 8.2. GlaxoSmithKline plc
    • 8.2.1. Company overview
    • 8.2.2. Key Executives
    • 8.2.3. Company snapshot
    • 8.2.4. Operating business segments
    • 8.2.5. Product portfolio
    • 8.2.6. Business performance
  • 8.3. Johnson & Johnson
    • 8.3.1. Company overview
    • 8.3.2. Key Executives
    • 8.3.3. Company snapshot
    • 8.3.4. Operating business segments
    • 8.3.5. Product portfolio
    • 8.3.6. Business performance
  • 8.4. Merck & Co., Inc.
    • 8.4.1. Company overview
    • 8.4.2. Key Executives
    • 8.4.3. Company snapshot
    • 8.4.4. Operating business segments
    • 8.4.5. Product portfolio
    • 8.4.6. Business performance
  • 8.5. Novartis AG
    • 8.5.1. Company overview
    • 8.5.2. Key Executives
    • 8.5.3. Company snapshot
    • 8.5.4. Operating business segments
    • 8.5.5. Product portfolio
    • 8.5.6. Business performance
    • 8.5.7. Key strategic moves and developments
  • 8.6. Pfizer Inc.
    • 8.6.1. Company overview
    • 8.6.2. Key Executives
    • 8.6.3. Company snapshot
    • 8.6.4. Operating business segments
    • 8.6.5. Product portfolio
    • 8.6.6. Business performance
  • 8.7. Sanofi S.A.
    • 8.7.1. Company overview
    • 8.7.2. Key Executives
    • 8.7.3. Company snapshot
    • 8.7.4. Operating business segments
    • 8.7.5. Product portfolio
    • 8.7.6. Business performance
  • 8.8. Bayer AG
    • 8.8.1. Company overview
    • 8.8.2. Key Executives
    • 8.8.3. Company snapshot
    • 8.8.4. Operating business segments
    • 8.8.5. Product portfolio
    • 8.8.6. Business performance
  • 8.9. Cipla Ltd
    • 8.9.1. Company overview
    • 8.9.2. Key Executives
    • 8.9.3. Company snapshot
    • 8.9.4. Operating business segments
    • 8.9.5. Product portfolio
    • 8.9.6. Business performance
  • 8.10. Amgen Inc.
    • 8.10.1. Company overview
    • 8.10.2. Key Executives
    • 8.10.3. Company snapshot
    • 8.10.4. Operating business segments
    • 8.10.5. Product portfolio
    • 8.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 02. PHARMACEUTICAL DRUG DELIVERY MARKET FOR ORAL DRUG DELIVERY, BY REGION, 2022-2032 ($BILLION)
  • TABLE 03. PHARMACEUTICAL DRUG DELIVERY MARKET FOR NASAL DRUG DELIVERY, BY REGION, 2022-2032 ($BILLION)
  • TABLE 04. PHARMACEUTICAL DRUG DELIVERY MARKET FOR OCULAR DRUG DELIVERY, BY REGION, 2022-2032 ($BILLION)
  • TABLE 05. PHARMACEUTICAL DRUG DELIVERY MARKET FOR TOPICAL DRUG DELIVERY, BY REGION, 2022-2032 ($BILLION)
  • TABLE 06. PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHER DRUG DELIVERY, BY REGION, 2022-2032 ($BILLION)
  • TABLE 07. GLOBAL PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 08. PHARMACEUTICAL DRUG DELIVERY MARKET FOR CANCER, BY REGION, 2022-2032 ($BILLION)
  • TABLE 09. PHARMACEUTICAL DRUG DELIVERY MARKET FOR DIABETES, BY REGION, 2022-2032 ($BILLION)
  • TABLE 10. PHARMACEUTICAL DRUG DELIVERY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022-2032 ($BILLION)
  • TABLE 11. PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHERS, BY REGION, 2022-2032 ($BILLION)
  • TABLE 12. PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION, 2022-2032 ($BILLION)
  • TABLE 13. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 14. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 15. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($BILLION)
  • TABLE 16. U.S. PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 17. U.S. PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 18. CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 19. CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 20. MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 21. MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 22. EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 23. EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 24. EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($BILLION)
  • TABLE 25. GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 26. GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 27. FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 28. FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 29. UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 30. UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 31. ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 32. ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 33. SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 34. SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 35. REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 36. REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 37. ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 38. ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 39. ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($BILLION)
  • TABLE 40. JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 41. JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 42. CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 43. CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 44. INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 45. INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 46. AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 47. AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 48. SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 49. SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 50. REST OF ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 51. REST OF ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 52. LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 53. LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 54. LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($BILLION)
  • TABLE 55. BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 56. BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 57. SAUDI ARABIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 58. SAUDI ARABIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 59. SOUTH AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 60. SOUTH AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 61. REST OF LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 62. REST OF LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 63. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 64. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 65. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 66. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 67. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 68. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 69. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
  • TABLE 70. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 71. JOHNSON & JOHNSON: KEY EXECUTIVES
  • TABLE 72. JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • TABLE 73. JOHNSON & JOHNSON: PRODUCT SEGMENTS
  • TABLE 74. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
  • TABLE 75. MERCK & CO., INC.: KEY EXECUTIVES
  • TABLE 76. MERCK & CO., INC.: COMPANY SNAPSHOT
  • TABLE 77. MERCK & CO., INC.: PRODUCT SEGMENTS
  • TABLE 78. MERCK & CO., INC.: PRODUCT PORTFOLIO
  • TABLE 79. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 80. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 81. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 82. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 83. NOVARTIS AG: KEY STRATERGIES
  • TABLE 84. PFIZER INC.: KEY EXECUTIVES
  • TABLE 85. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 86. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 87. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 88. SANOFI S.A.: KEY EXECUTIVES
  • TABLE 89. SANOFI S.A.: COMPANY SNAPSHOT
  • TABLE 90. SANOFI S.A.: PRODUCT SEGMENTS
  • TABLE 91. SANOFI S.A.: PRODUCT PORTFOLIO
  • TABLE 92. BAYER AG: KEY EXECUTIVES
  • TABLE 93. BAYER AG: COMPANY SNAPSHOT
  • TABLE 94. BAYER AG: PRODUCT SEGMENTS
  • TABLE 95. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 96. CIPLA LTD: KEY EXECUTIVES
  • TABLE 97. CIPLA LTD: COMPANY SNAPSHOT
  • TABLE 98. CIPLA LTD: PRODUCT SEGMENTS
  • TABLE 99. CIPLA LTD: PRODUCT PORTFOLIO
  • TABLE 100. AMGEN INC.: KEY EXECUTIVES
  • TABLE 101. AMGEN INC.: COMPANY SNAPSHOT
  • TABLE 102. AMGEN INC.: PRODUCT SEGMENTS
  • TABLE 103. AMGEN INC.: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN PHARMACEUTICAL DRUG DELIVERY MARKET (2023-2032)
  • FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. LOW THREAT OF NEW ENTRANTS
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALPHARMACEUTICAL DRUG DELIVERY MARKET
  • FIGURE 10. PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR ORAL DRUG DELIVERY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR NASAL DRUG DELIVERY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR OCULAR DRUG DELIVERY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR TOPICAL DRUG DELIVERY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHER DRUG DELIVERY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR CANCER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR DIABETES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. PHARMACEUTICAL DRUG DELIVERY MARKET BY REGION, 2022
  • FIGURE 22. U.S. PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 23. CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 24. MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 25. GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 26. FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 27. UK PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 28. ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 29. SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 30. REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 31. JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 32. CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 33. INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 34. AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 35. SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 36. REST OF ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 37. BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 38. SAUDI ARABIA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 39. SOUTH AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 40. REST OF LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 44. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 45. COMPETITIVE DASHBOARD
  • FIGURE 46. COMPETITIVE HEATMAP: PHARMACEUTICAL DRUG DELIVERY MARKET
  • FIGURE 47. TOP PLAYER POSITIONING, 2022
  • FIGURE 48. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 49. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 50. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 52. GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 53. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 55. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 56. MERCK & CO., INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 57. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 58. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 59. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 60. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 61. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 62. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 63. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 64. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 65. SANOFI S.A.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 66. SANOFI S.A.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 67. SANOFI S.A.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 68. BAYER AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 69. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 70. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 71. CIPLA LTD: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 72. CIPLA LTD: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 73. CIPLA LTD: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 74. AMGEN INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 75. AMGEN INC.: REVENUE SHARE BY REGION, 2022 (%)